Table 1.
Clinical trials of PRRT with alpha-emitters or somatostatin antagonists in patients with NETs.
| Therapeutic Agent | Dosage and Schedule | Patient Population | Number of Patients Enrolled | Objective Responses * (RECIST 1.1) |
Reference |
|---|---|---|---|---|---|
| 225 Ac-DOTATATE | Systemic infusion every 8 weeks (100 kBq/kg of body weight) |
Advanced GEP-NETs stable or progressing on 177Lu-DOTATATE | 32 | ORR: 62% (62% PR; 38% SD) |
[17] |
| 213 Bi-DOTATOC | Intra-arterial or systemic infusion every 8 weeks (first cycle: 1GBq; second cycle: 1.5 GBq; third cycle: 2–4 GBq; fourth cycle: as available from the generator) |
Advanced NETs with liver metastases progressing on 90Y/177Lu-DOTATOC therapy | 7 | ORR: 50% (17% CR; 33% PR; 50% SD) |
[18] |
| 212 Pb-DOTAMTATE | Systemic infusion every 8 weeks (3+3 dose escalation design) |
Advanced SSTR+ NETs | 50 | ORR at highest dose cohort: 83% (1 CR; 5 PR) |
[20] |
| 177 Lu-DOTA-JR11 | Systemic infusion every 12 weeks (cumulative absorbed bone marrow dose up to 1 Gy) |
Advanced, well-differentiated, SSTR+ NETs | 20 | ORR: 45% (5% CR; 40% PR) |
[22] |
* Among evaluable patients. NET: neuroendocrine tumor; RECIST: Response Evaluation Criteria in Solid Tumors; ORR: objective response rate; SD: stable disease; CR: complete response; PR: partial response; SSTR+: somatostatin receptor positive; PRRT: peptide receptor radionuclide therapy.